Abiomed Readies New Products In Wake Of Negative FDA Panel Vote
This article was originally published in The Gray Sheet
Executive Summary
Abiomed has commitments from several major clinical centers to conduct trials for its Recover 2.5 and 5.0 second-generation cardiac micropumps, following investigational device exemption submissions to FDA
You may also be interested in...
Zoll Takes Aim At Hospital Defibrillator Market In 2007; Stock Up 131% In ’06
External defibrillator maker Zoll Medical's success in the pre-hospital emergency medical services market in 2006, and prospects for its advanced R Series defibrillator in the hospital sector in 2007, helped to hearten investors last year and propel the firm's stock price ahead 131%
Zoll Takes Aim At Hospital Defibrillator Market In 2007; Stock Up 131% In ’06
External defibrillator maker Zoll Medical's success in the pre-hospital emergency medical services market in 2006, and prospects for its advanced R Series defibrillator in the hospital sector in 2007, helped to hearten investors last year and propel the firm's stock price ahead 131%
AbioCor Artificial Heart Gets FDA Humanitarian Device Exemption
The first fully implantable artificial heart, more than 25 years in the making, received approval from FDA Sept. 5 as a humanitarian-use device